Maplight Therapeutics Announces Completion Of Phase 1 Clinical Trial For Ml-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias
18.08.2022 Maplight Therapeutics Announces Completion Of Phase 1 Clinical Trial For Ml-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias First in human
MapLight announces initiation of Phase 1 Clinical Trials to treat patients with Schizophrenia or Dyskinesias
Initial study is enrolling healthy patients across seven cohorts to assess safety, tolerability, and pharmacokinetic profile related to ML-007 therapy.
The $1.75M award builds on a $5.5M grant from MJFF announced earlier this month. MapLight also received an $8.1M award from MJFF in 2020.
MapLight’s promising platform continues to garner support from leading Parkinson’s research foundation.
Dr. Foff Joins MapLight to Help Further Advance the Company’s Portfolio of Novel Therapeutics for Patients with Disorders of the Central Nervous System (CNS).
Results will inform identification of novel drug targets and therapeutic strategies to address anxiety and depression related to Parkinson’s disease neurodegeneration.
MapLight Therapeutics announces completion of dosing in Phase 1 Study of therapy for Social Deficit in Autism Spectrum Disorder
Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004.
This new grant totaling more than $16.5 million will serve our mission to find a cure for Parkinson’s and improved treatments for those living with the disease today.